For investors

Helixir generates biology.

Most AI for biology retrieves and summarises what is already known. Helixir generates novel hypotheses and de novo designs, then returns the evidence, disagreement, and limitations needed to audit the result.

What is built

A working technical foundation, measured in public.

Helixir runs structured programs for hypothesis discovery, protein design, trial design, and related scientific work. The same system connects a multi-agent scientific harness, a living project graph, published research, and a UCF wet-lab collaboration for experimental follow-up.

4Specialist Co-Scientists
193M+Entities in the September graph snapshot
484M+Evidence-typed relations
2Published models and benchmarks
Team

Scientific depth and operating experience.

Founding CEO

Dr. Ivan Garibay

Director of the Complex Adaptive Systems Laboratory at UCF; research in complex systems, evolutionary computation, and multi-agent systems.

Founding COO

Dr. Edwin Nassiff

Former CTO of Enterprise Information Systems at Lockheed Martin and former CIO in the US Government.

Founding CTO

Dr. Sanjay Padhi

Former Head of AWS Research, CTO of Tag.bio, and co-architect of Helixir.

Head of Commercialization

Mark Pitman

More than twenty years building and scaling biotechnology companies.

Meet the team and research collaborators →
Investor brief

Take the one-page overview.

Share your work email and the current brief will unlock here. The form routes to the same investor inbox used by the rest of the site.

Your details go to the DeepBio Scientific investor inbox and are used only to follow up on this request.